Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated, recurrent epithelial ovarian cancer

被引：0
|
作者：
Hurt, J. [1 ]
Backes, F. [1 ]
Rheaume, S. [1 ]
Richardson, D. [1 ]
Fowler, J. [1 ]
Copeland, L. [1 ]
Cohn, D. [1 ]
Eisenhauer, E. [1 ]
Salani, R. [1 ]
O'Malley, D. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [21] Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer
    Ikeda, Yuji
    Kikuchi, Yoshihiro
    Takano, Masashi
    Goto, Tomoko
    Kouta, Hiroko
    Sasaki, Naoki
    Kudoh, Kazuya
    Oda, Katsutoshi
    Nagasaka, Tsuneki
    Kita, Tsunekazu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
    Martin, Jovana Y.
    Urban, Renata R.
    Liao, John B.
    Goff, Barbara A.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (05)
  • [23] DIFFERENCES IN CORRELATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL BY CLINICAL VARIABLES IN EPITHELIAL OVARIAN CANCER
    Paik, E. S.
    Jeong, S. Y.
    Kim, M. S.
    Kim, J. H.
    Kim, T. J.
    Lee, J. W.
    Kim, B. G.
    Bae, D. S.
    Choi, C. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 717 - 717
  • [24] DIFFERENCES IN CORRELATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL BY CLINICAL VARIABLES IN EPITHELIAL OVARIAN CANCER
    Paik, E. S.
    Kang, M.
    Lee, J. H.
    Kang, J. H.
    Jeong, S. Y.
    Kim, M. S.
    Lee, Y-Y
    Kim, T-J
    Lee, J-W
    Kim, B-G
    Bae, D-S
    Seo, J.
    Choi, C. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A504 - A505
  • [25] THE EFFECT OF SINGLE WEEKLY PACLITAXEL IN HEAVILY PRETREATED OVARIAN CANCER PATIENTS AND ITS ANTIANGIOGENIC EFFECTS
    Kikuchi, Yoshihiro
    Kita, Tsunekazu
    Takano, Masashi
    Kudoh, Kazuya
    Saito, Keiko
    Fujii, Kazuyuki
    Sasaki, Naoki
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3535 - 3535
  • [26] Cetuximab significantly improves progression-free survival and disease control in metastatic colorectal cancer patients
    不详
    ONCOLOGY-NEW YORK, 2007, 21 (06): : 739 - 739
  • [27] Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer
    Lee, Chee K.
    Friedlander, Michael
    Brown, Chris
    Gebski, Val J.
    Georgoulopoulos, Alexander
    Vergote, Ignace
    Pignata, Sandro
    Donadello, Nicoletta
    Schmalfeldt, Barbara
    Delva, Remy
    Mirza, Mansoor Raza
    Sauthier, Philippe
    Pujade-Lauraine, Eric
    Lord, Sarah J.
    Simes, R. John
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17) : 1338 - U7
  • [28] Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
    Yumei Zhou
    Junfen Xu
    World Journal of Surgical Oncology, 22 (1)
  • [29] Vandetanib improves progression-free survival in lung cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (07) : 378 - 378
  • [30] THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON PROGRESSION-FREE INTERVAL AND SURVIVAL IN EPITHELIAL OVARIAN-CANCER
    HOSKINS, WJ
    BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1989, 3 (01): : 59 - 71
12345